<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                               NIH Public Access <br />                                Author Manuscript <br />                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                            Published final edited form  <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Cell Metab. 2012 November 7; 16(5): 645&#226;&#8364;&#8220;657. doi:10.1016/j.cmet.2012.10.001. <br />  <br />  <br />  <br />                            mTOR Regulates Cellular <span id='am-29' about='obo:IMR_0200435' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-30' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:id" content="IMR:0200435" datatype="xsd:string"></span><span id='am-32' property="oboInOwl:hasDbXref" content="KEGG:C00023" datatype="xsd:string"></span><span id='am-33' property="rdfs:label" content="Iron" datatype="xsd:string"></span>Iron</span> Homeostasis                            Tristetraprolin <br />                            Marina Bayeva1, Arineh Khechaduri1, Sergi Puig2, Hsiang-Chun Chang1, Sonika Patial3, <br />                            Perry J. Blackshear3, Hossein Ardehali1,* <br />                            1Feinberg Cardiovascular Research Institute, Northwestern University School Medicine, <br />  <br />                            Chicago, 60611, USA <br />                            2Departamento Biotecnolog&#195;&#173;a, Instituto Agroqu&#195;&#173;mica y Tecnolog&#195;&#173;a Alimentos (IATA- <br />                            CSIC), P.O. Box 73, E-46100 Burjassot, Valencia, Spain <br />                            3Laboratory Signal Transduction; National Institute Environmental Health Science; Research <br />                            Triangle Park, NC 27709, USA <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            SUMMARY <br />                                  Iron essential cofactor unique redox properties. Iron regulatory proteins 1 2 <br />                                  (IRP1/2) established important regulators cellular iron homeostasis, little                                  known role pathways process. report mammalian target <br />                                  <span id='am-6' about='obo:IMR_0002818' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-7' property="rdfs:label" content="rapamycin" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:hasDbXref" content="KEGG:C07909" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-10' property="oboInOwl:id" content="IMR:0002818" datatype="xsd:string"></span>rapamycin</span> (mTOR) regulates iron homeostasis modulating transferrin receptor 1 (TfR1) <br />                                  stability altering cellular iron flux. Mechanistic studies identify tristetraprolin (TTP), protein <br />                                  involved anti-inflammatory response, downstream target mTOR binds                                  enhances degradation TfR1 mRNA. TTP strongly induced iron <br />                                  chelation, promotes downregulation iron-requiring genes mammalian yeast cells, <br />                                  modulates survival low-iron states. Taken  data uncover link                                  metabolic, inflammatory, iron regulatory pathways, point existence                                  yeast-like TTP-mediated iron conservation program mammals. <br />  <br />  <br />                            INTRODUCTION <br />                                               Iron deficiency anemia affects quarter world&#226;&#8364;&#8482;s population   2008),                                               mechanisms iron regulation remain largely unexplored. Iron essential micronutrient <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               required fundamental biological processes including oxygen delivery, protein synthesis, <br />                                               DNA replication oxidative phosphorylation (Arredondo Nunez, 2005).  <br />                                               ability iron easily gain lose electrons facilitates production reactive <br />                                               oxygen species (ROS) Fenton reaction (Aisen et al., 2001).  iron levels                                               tightly controlled cellular systemic levels deregulation iron homeostasis                                               associated aging, metabolic disorders cancer (Aisen et al., 2001; Altamura                                               Muckenthaler, 2009; Torti Torti, 2011; Weinberg, 2010). <br />  <br />  <br />  <br />  <br />                            &#194;&#169; 2012 Elsevier  rights reserved. <br />                            * <br />                             Correspondence: h-ardehali@northwestern.edu. <br />                            Publisher&apos;s Disclaimer: PDF file unedited manuscript accepted publication. service                            customers providing early version manuscript. manuscript undergo copyediting, typesetting, review                            resulting proof published final citable form. note production process errors                            discovered affect content, legal disclaimers apply journal pertain. <br />                            authors declare conflicts                             Bayeva et al.                                                                                             Page 2 <br />  <br />  <br />                                            Maintenance cellular iron homeostasis dependent RNA-binding iron regulatory <br />                                            proteins 1 2 (IRP1/2) activated iron-deficient conditions. IRP1/2 <br />                                            function restore iron levels  1) stabilization transferrin receptor 1 (TfR1) <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            mRNA increased iron uptake, 2) mobilization cellular iron stores, 3) reduction                                            cellular iron export suppression ferroportin 1 (Fpn1), cellular iron <br />                                            exporter identified <span id='am-11' about='oboInOwl:date' typeof='owl:Thing'>date</span> (Hentze et al., 2010; Rouault, 2006; Wang Pantopoulos, <br />                                            2011). Additionally, iron conservation response recently described S. <br />                                            cerevisiae coordinated expression tandem zinc finger (TZF) proteins Cth1p                                            Cth2p causes destabilization mRNAs nonessential iron-containing proteins                                            libration iron use vital processes (Pedro-Segura et al., 2008; Puig et al., 2005; Puig <br />                                            et al., 2008). mammalian homolog Cth1p/Cth2p, tristetraprolin (TTP),                                            extensively studied context immunosuppression (Baou et al., 2009), role                                            iron regulation known. <br />  <br />                                            Mammalian target rapamycin (mTOR) important sensor cellular energy state                                            major hub integration environmental cues (Howell Manning, 2011; Sengupta et <br />                                            al., 2010). complex activated energetically favorable, low-stress states                                            adverse conditions, starvation, cytotoxic insults DNA damage, act inhibit <br />                                            mTOR signaling promote survival conservation cellular resources (Dunlop <br />                                            Tee, 2009; Soliman, 2005). processes governed mTOR dependent                                            iron factor require steady supply metal. appears NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            link iron homeostasis mTOR, clinical use rapamycin associated                                            development microcytic anemia mechanistically distinct anemia                                            chronic disease (Kim et al., 2006; Maiorano et al., 2006; Sofroniadou et al., 2010).                                             establish mTOR pathway regulator iron homeostasis acts modulation <br />                                            iron transporters alteration cellular iron flux.  identify TTP                                            target mTOR   modulates iron-regulatory effects                                            destabilization TfR1 mRNA. <br />  <br />                               RESULTS <br />                               mTOR regulates cellular iron homeostasis <br />                                            mTOR activation stimulates important anabolic processes depend                                            presence iron cofactor;  hypothesized mTOR play role                                            regulation cellular iron availability utilization. test  modulated mTOR <br />                                            signaling wild type (WT) mouse embryonic fibroblasts (MEFs) H9c2 cardiac <br />                                            myoblasts followed quantification heme non-heme iron content. Rapamycin <br />                                            effectively inhibited mTOR signaling cell lines (Figure 1A), assessed                                            ablation pS6 expression. Treatment rapamycin led significant increase NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            non-heme heme iron content MEFs (Figure 1B S1A) H9c2 cells (Figure <br />                                            S1B,C). Consistent elevation iron levels, protein content ferritin light chain,                                            iron storage molecule, significantly increased rapamycin treatment WT MEFs <br />                                            (Figure S1D). Increased heme levels likely inhibition heme degradation,                                            mRNA levels heme oxygenase 1 (HMOX1) significantly decreased,                                            expression key heme synthetic enzymes, &#206;&#180;-aminolevulinic acid synthase 1 (ALAS1)                                            ferrochelatase, remained unchanged (Figure S1E). activate mTOR, used TSC2 <br />                                            knockout MEFs upstream inhibitor pathway genetically deleted                                            pS6 levels increased (Figure 1A). knockout MEFs transfected                                            pEF6 vector (referred TSC2 KO-V MEFs) pEF6/TSC2 vector                                            reconstitute TSC2 expression knockout MEFs (TSC2 KO-TSC2 MEFs), followed                                            selection blasticidin generate stable transgenic cell lines described (Zhang et al., <br />                                            2003). Constitutive activation mTOR TSC2 KO-V MEFs decreased heme non- <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                            Page 3 <br />  <br />  <br />                                            heme iron, rapamycin restored levels control (Figure 1C S1F), <br />                                            indicating observed changes mTOR modulation. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            determine changes cellular iron resulted alterations iron import,                                            measured uptake radioactive iron (55Fe) mTOR modulation. Unexpectedly, <br />                                            rapamycin treatment significantly reduced iron uptake, TSC2 KO-V MEFs TSC2 <br />                                            siRNA-treated H9c2 myoblasts displayed enhancement iron uptake 60 minutes                                            incubation (Figure 1D,E S1G,H). differences persisted 24 hours                                            growth 55Fe cell lines (Figure 1F,G S1I,J). results suggest                                            inhibition mTOR results cellular iron accumulation despite reduction iron uptake, <br />                                            mTOR activation opposite effect. <br />  <br />                                            studied mechanism observations measuring expression genes <br />                                            involved iron regulation MEFs H9c2 (Anderson Vulpe, 2009; Hentze et al., <br />                                            2010). Consistent decreased iron uptake, rapamycin significantly reduced                                            mRNA protein levels transferrin receptor 1 (TfR1) required uptake                                            transferrin-bound iron (Figure 2A,C). Additionally, TfR1 levels reduced MEFs                                            H9c2 treated Torin-1, specific inhibitor mTOR pathway (Figure S2A). <br />                                             mRNA protein levels iron exporter, Fpn1, reduced                                            rapamycin Torin-1 (Figure 2B,C, Figure S2A). Consistently, mTOR activation <br />                                            increased expression TfR1 Fpn1, rapamycin suppressed effect (Figure <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            2D). results suggest mTOR inhibition leads coordinated reduction                                            expression TfR1 Fpn1, resulting net accumulation cellular iron, mTOR <br />                                            activation opposite effect. <br />  <br />                                            addition effects TfR1 Fpn1, rapamycin led global suppression                                            iron-regulatory genes MEFs H9c2, consistent reduction cellular iron flux, <br />                                            opposite observed activation mTOR (Figure S2B&#226;&#8364;&#8220;E). contrary,                                            downregulation genes involved regulation cellular iron                                            rapamycin treatment WT MEFs (Figure 2E), suggesting effects iron regulatory <br />                                            network specific, represent artifact generalized transcriptional <br />                                            repression. <br />  <br />                               TfR1 target mTOR <br />                                            Concurrent decrease expression protein mediating iron import (TfR1) iron <br />                                            exporter (Fpn1) rapamycin raises possibilities.  mTOR inhibition                                            negatively regulate expression TfR1, leading reduced iron import net iron loss <br />                                            cell. resulting deficiency activate IRP1/2 subsequent inhibition                                            Fpn1 prevent iron loss (Figure S3A). Alternatively, rapamycin primarily <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            target Fpn1 leading cellular iron accumulation decreased export.                                            suppress IRP1/2 activity secondarily reduce TfR1 levels stop iron gain                                            import (Figure S3B). distinguish possibilities, assessed time- <br />                                            course TfR1 Fpn1 expression 24 hours rapamycin treatment.                                            observed steady decrease TfR1 mRNA levels rapamycin, Fpn1 expression <br />                                            initially upregulated 2 4 hours, followed decline (Figure 3A). findings <br />                                            point possibility mTOR primarily regulating TfR1 expression,                                            changes Fpn1 secondary effect (Figure S3A). Consequently, focused                                            efforts studying regulation TfR1 mTOR. <br />  <br />                                            uncover mechanism mTOR regulates TfR1, assessed stability <br />                                            TfR1 mRNA rapamycin treatment. Incubation rapamycin-treated MEFs                                            transcriptional inhibitor actinomycin D led significant reduction TfR1 mRNA <br />                                            stability relative control group (Figure 3B), suggestive post-transcriptional <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                            Page 4 <br />  <br />  <br />                                            regulation. key known post-transcriptional regulators TfR1 IRP1/2 proteins, <br />                                             hypothesized, mediate mTOR-dependent changes TfR1. determine <br />                                            IRP1/2 pathway mediates suppression TfR1 rapamycin, downregulated IRP1 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            expression IRP2 KO MEFs using siRNA approach (IRP1/2 KD/KO MEFs),                                            resulted significant knockdown IRP1 expression (Figure 3C) reduction TfR1 <br />                                            mRNA, consistent functional inhibition IRP1/2 pathway (Figure S3C). <br />                                             repression TfR1 rapamycin intact IRP1/2 KD/KO MEFs <br />                                            (Figure 3D), indicating regulation TfR1 mTOR independent IRP1/2 <br />                                            pathway. <br />  <br />                               TTP functionally similar iron-regulating yeast Cth1p/Cth2p proteins <br />                                            Recent studies S. cerevisiae TZF proteins, Cth1p Cth2p, regulate cellular <br />                                            iron homeostasis binding AU-rich elements (AREs) destabilizing mRNAs                                            iron-requiring proteins salvaging iron use essential functions (Puig et al., 2005). <br />                                            showed IRP1/2 proteins mediate effects mTOR TfR1,                                            hypothesized TZF proteins regulate TfR1 cellular iron homeostasis                                            mammals. TZF proteins homology Cth1p Cth2p, TTP (ZFP36), CMG1 <br />                                            (Zfp36l1) TIS11D (Zfp36l2), identified mammals (Baou et al., 2009)                                            studied context cytokine signaling (Carrick et al., 2004). determine                                            proteins modulate iron homeostasis similar Cth1p/Cth2p yeast, assessed <br />                                            regulation cellular iron levels. Iron chelation DFO resulted significant NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            dose-dependent upregulation TTP mRNA (Figure 3E) protein expression (Figure 3F). <br />                                            Treatment 2,2&#226;&#8364;&#8220;bipyridyl (2,2-BPD), lipophilic iron chelator mechanistically <br />                                            distinct DFO, induced TTP expression (Figure 3G), suggesting observed <br />                                            effect reduction cellular iron restricted DFO.  <br />                                            iron overload ferric ammonium citrate (FAC) suppressed TTP expression (Figure 3G). <br />                                            mRNA levels TZF proteins increased DFO MEFs                                            H9c2 cells (Figure S3D,E),  excluded subsequent studies                                            lack regulation mTOR (Figure S3F,G). Taken  results  similar <br />                                            Cth1p/Cth2p yeast, TTP regulated cellular iron status mammals. <br />  <br />                                            confirm functional similarity Cth1p/Cth2p TTP, studied                                            ability TTP reduce expression containing iron-requiring proteins (ABCE1, <br />                                            Fe/S cluster protein involved ribosome biogenesis Lias, lipoic acid synthase) <br />                                            (Figure S3H). Similar yeast, iron chelation reduced expression ABCE1 Lias                                            WT MEFs (Figure 3H), did suppress mRNA levels proteins                                            require iron function (Figure S3I).  mRNA levels ABCE1 Lias <br />                                            increased TTP KO MEFs (Figure 3I S3J), ABCE1 levels reduced                                            TTP overexpression WT MEFs (Figure S3J,K), confirming inhibitory function NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            TTP. DFO treatment TTP KO MEFs failed decrease, instead led                                            exaggerated increase expression ABCE1 Lias (Figure 3J), suggesting TTP <br />                                            critical repression iron-containing proteins iron chelation. Finally,                                            determine mammalian TTP complement Cth1p/Cth2p deletion yeast,                                            expressed WT TZF-mutant allele human TTP (C124R) (Lai et al., 1999)                                            control iron-regulated CTH2 promoter yeast cells. Similar MEFs, treatment <br />                                            Cth1&#206;&#8221;Cth2&#206;&#8221; yeast iron chelator bathophenanthroline (BPS) led increase                                            mRNA levels known Cth1p/Cth2p targets, succinate dehydrogenase subunit 4 <br />                                            (SDH4) aconitase (ACO1), transfection cells Cth2 plasmid restored <br />                                            suppression iron-containing genes iron deficiency (Figure 3K).  <br />                                            overexpression WT human TTP, C124R construct, reduced mRNA levels <br />                                            SDH4 ACO1 iron-limiting conditions, suggestive functional conservation <br />                                            yeast Cth1p/Cth2p mammalian TTP (Figure 3K). Taken  findings <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                            Page 5 <br />  <br />  <br />                                            suggest role TTP regulation cellular iron homeostasis similar                                            performed yeast Cth1p/Cth2p, suppressing expression iron-containing <br />                                            proteins potentially optimizing iron utilization low-iron states. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               mTOR regulates TTP expression <br />                                             assessed mTOR regulates expression TTP. Rapamycin treatment                                            MEFs H9c2 cells induced expression TTP mRNA protein (Figure 4A,B                                            S4A). Significant upregulation TTP mRNA observed Torin-1 treated MEFs <br />                                            H9c2 cells (Figure S4B,C). TTP levels suppressed mTOR activation TSC2 <br />                                            KO-V MEFs, rapamycin reversed effects (Figure 4C).  rapamycin <br />                                            treatment WT MEFs resulted significant decrease levels stability TTP <br />                                            targets ABCE1 Lias, consistent TTP induction (Figure S4D,E). Treatment cells <br />                                            rapamycin DFO led greater induction TTP expression agent <br />                                            (Figure S4F), suggesting additive effect. Importantly, downstream effects                                            TTP rapamycin iron regulation independent inflammatory response,                                            did detect TNF&#206;&#177; mRNA expression MEFs H9c2 cells (Figure S4G,H). Finally, <br />                                            determine regulation TZF proteins mTOR conserved                                            eukaryotic organisms, treated WT yeast strain rapamycin observed significant <br />                                            induction Cth1 Cth2 mRNA (Figure 4D), consistent observations                                            mammalian cells. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            mTOR cellular iron status known regulate hypoxia-inducible factor <br />                                            (HIF) signaling, assessed TTP regulation aryl hydrocarbon receptor nuclear <br />                                            translocator (ARNT) KO MEFs lack obligate binding partner HIF1&#206;&#177; HIF2&#206;&#177;, <br />                                            disrupting HIF pathway (Patel Simon, 2008). TTP levels increased <br />                                            DFO rapamycin treatment ARNT KO MEFs (Figure 4E,F), indicating                                            observed regulation HIF-independent.  observed significant induction                                            TTP expression IRP1/2 KD/KO MEFs (Figure 4G,H), suggesting activity                                            IRP1/2 does mediate upregulation TTP expression rapamycin                                            DFO. summary, TTP negatively regulated mTOR pathway HIF- <br />                                            IRP1/2-independent manner. <br />  <br />                               TTP associates regulates TfR1 mRNA <br />                                            TTP modulates cellular iron homeostasis downstream target mTOR,                                            hypothesized TTP regulate TfR1. Computational analysis 3&#226;&#8364;&#8482;UTR TfR1 <br />                                            revealed multiple putative AREs, close proximity                                            overlapped IREs (Figure S5A). Consistently, TfR1 mRNA levels                                            increased TTP KO MEFs (Figure 4I) TTP siRNA H9c2 cells (Figure S5B), <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            TTP overexpression reduced TfR1 levels MEFs (Figure 4J).  TfR1 <br />                                            mRNA significantly stabilized TTP KO MEFs presence actinomycin D <br />                                            (Figure 4K), confirming TTP regulates TfR1 expression level mRNA stability. <br />  <br />                                            determine TTP regulates TfR1 mRNA 3&#226;&#8364;&#8482;UTR, cloned length <br />                                            3&#226;&#8364;&#8482;UTR mouse TfR1 downstream firefly luciferase gene (TfR1-3&#226;&#8364;&#8482;UTR-Luc, Figure <br />                                            5A), used renilla luciferase construct normalize transfection efficiency. Consistent <br />                                            TTP suppression TfR1 3&#226;&#8364;&#8482;UTR, transfection TfR1-3&#226;&#8364;&#8482;UTR-Luc construct <br />                                            WT MEFs overexpressing TTP led significant reduction luminescence signal <br />                                            (Figure 5B), luminescence increased TTP KO MEFs (Fig 5C). <br />  <br />                                            Finally, assess interaction TTP TfR1 mRNA, performed RNA  <br />                                            immunoprecipitation (RNA IP) experiment using anti-TTP control IgG antibody <br />                                            bait analyzing mRNA targets TTP qRT-PCR (Table 1), described previously <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                           Page 6 <br />  <br />  <br />                                            (Emmons et al., 2008). monoclonal antibody used studies raised                                            human TTP, pull experiments performed human HEK293 cells.                                            designed distinct primer sets TfR1 target regions near 3&#226;&#8364;&#8482;UTR, primer <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            sets positive controls. observed enrichment known targets TTP <br />                                            (VEGF (Essafi-Benkhadir et al., 2007) Pitx-2 (Briata et al., 2003)) TTP antibody <br />                                            group compared IgG, enrichment observed negative <br />                                            controls tested (Table 1). TfR1 mRNA levels significantly enriched TTP group <br />                                            compared IgG control (Table 1, Figure 5D), indicative interaction TTP <br />                                            TfR1 mRNA. Taken  results TTP induced rapamycin                                            regulates TfR1 expression posttranscriptional level. <br />  <br />                               mTOR regulates iron homeostasis TTP <br />                                            Finally, asked TTP mediates changes TfR1 expression observed                                            mTOR modulation. TTP KO MEFs incubated rapamycin, expression                                            TfR1 assessed. TTP WT MEFs, rapamycin led expected ~50% decrease                                            TfR1 levels;  TTP KO MEFs reduction TfR1 expression significantly <br />                                            blunted (Figure 5E). Furthermore, expression containing iron-requiring <br />                                            proteins reduced rapamycin WT MEFs, response greatly attenuated                                            TTP KO MEFs (Figure 5F). Finally, TfR1 mRNA stability reduced WT MEFs <br />                                            incubated rapamycin, TTP KO MEFs (Figure 5G). results establish <br />                                            TTP downstream target mTOR, activity partially responsible NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            mTOR-dependent regulation TfR1. <br />  <br />                                            shown TTP regulates TfR1 mRNA stability, significance TfR1 <br />                                            downregulation setting iron deficiency respect IRP1/2 pathway                                            unclear. hypothesized TTP acts &#226;&#8364;&#339;brake&#226;&#8364;? IRP1/2 prevent                                            unnecessary activation iron uptake cell reducing iron use TTP- <br />                                            dependent downregulation iron-containing proteins. correct, hypothesis predicts <br />                                            exaggerated induction TfR1 iron deficiency absence TTP, higher levels <br />                                            TTP blunt TfR1 upregulation iron chelation. Consistently,                                            degree TfR1 upregulation significantly greater DFO-treated TTP KO MEFs <br />                                            compared chelated TTP WT MEFs (Figure 5H), combination DFO                                            rapamycin, additive effect TTP upregulation (Figure S4F), led                                            attenuation TfR1 induction compared DFO (Figure S5C). <br />  <br />                                            assess functional importance TTP regulation cellular iron, measured                                            survival TTP KO MEFs iron-deficient conditions. hypothesized TTP                                            protective low iron states, deletion result increased cell death iron <br />                                            chelation. Consistently, observed significant drop cell viability TTP KO MEFs <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            treated 250&#194;&#181;M DFO 250&#194;&#181;M 2,2-BPD 40 hrs (Figure 5I). addition, TTP KO <br />                                            MEFs exquisitely sensitive serum deprivation (Figure S5D), main <br />                                            source iron growth medium (Kakuta et al., 1997), glutamine deprivation <br />                                            (Figure S5D), indicative tolerance TTP KO MEFs general cellar stressors. <br />                                            Supplementation TTP KO MEFs transferrin-bound iron significantly,                                            completely, reversed effects serum deprivation cell viability, effect <br />                                            viability TTP KO MEFs grown serum-replete medium (Figure S5E). findings <br />                                            suggest TTP KO MEFs reduced cell viability deprived iron compared                                            TTP WT MEFs. <br />  <br />                                            determine cell death iron-deficient TTP KO MEFs mediated mTOR <br />                                            pathway, pre-treated TTP KO MEFs rapamycin 6 hours, followed  <br />                                            incubation DFO 2,2-BPD. Surprisingly, rapamycin significantly attenuated cell <br />                                            death iron chelation (Figure 5J). Analysis cell cycle progression revealed <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                          Page 7 <br />  <br />  <br />                                            significantly higher baseline division rates TTP KO MEFs compared TTP WT MEFs <br />                                            (Figure S5F), defect cell cycle arrest response DFO (Figure S5G,H).                                            hand, pre-treatment TTP KO MEFs rapamycin prior chelation DFO NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            equally suppressed cell cycle progression TTP KO TTP WT MEFs (Figure S5G,H), <br />                                            suggesting rapamycin-dependent preservation viability TTP KO MEFs                                            suppression cell division TTP KO MEFs. <br />  <br />                                            summary, results suggest mTOR regulates cellular iron homeostasis TfR1 <br />                                            expression TTP inhibition function negative feedback loop fine- <br />                                            tune iron deficiency response maintain cell viability low-iron states. <br />  <br />                               mTOR TTP regulate iron homeostasis vivo <br />                                            far data suggest mTOR TTP regulate expression TfR1 iron <br />                                            homeostasis MEFs H9c2 cells. determine pathways play role                                            regulation iron homeostasis vivo, treated c57 black WT mice 5 daily <br />                                            intraperitoneal (IP) injections rapamycin inhibit mTOR, studied iron <br />                                            regulation triple TTP- TNF&#206;&#177; receptors 1 2 knockout (TTP/TNFR1/2 KO) mice. <br />                                            mice deletion TTP display profound inflammation primarily                                            stabilization TNF&#206;&#177; (Taylor et al., 1996), TTP/TNFR1/2 triple-KO mice                                            inflammatory phenotype year age (Carballo Blackshear, 2001)                                            represent suitable model study iron regulation. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Treatment WT mice IP rapamycin successfully inhibited mTOR signaling,                                            evidenced absence pS6 expression (Figure S6A). Similar vitro findings, <br />                                            nonheme heme iron levels increased (Figure 6A,B), expression TfR1 <br />                                            Fpn1 reduced (Figure 6C,D), hearts rapamycin-treated mice. TTP <br />                                            expression induced rapamycin mouse hearts (Figure 6D), suggesting                                            protein potentially mediate TfR1 expression vivo. Surprisingly, assessment                                            rapamycin effects hepatic iron homeostasis revealed reduced non-heme iron levels <br />                                            (Figure S6B) decrease TfR1, preservation Fpn1 expression (Figure S6C,D). <br />                                            suggests rapamycin primarily reduces uptake iron liver, leading                                            export-dependent iron loss. Finally, rapamycin effect expression                                            systemic iron-regulatory hormone hepcidin upstream regulators, bone <br />                                            morphogenic protein 6 (BMP6) hemojuvelin (HJV) (Figure S6E).  rapamycin <br />                                            appears primarily affect iron regulation cellular level vitro vivo. <br />  <br />                                            assessed effects TTP deletion iron regulation TTP/TNFR1/2 KO                                            WT littermate control mice. Consistent vitro findings, TfR1 protein levels                                            significantly induced TTP-deficient mouse hearts (Figure 6E), corresponded NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            increase cardiac non-heme iron content (Figure 6F) elevated levels iron storage <br />                                            protein ferritin (light heavy chains) (Figure 6G).  reduction                                            levels Fpn1 protein TTP deletion (Figure 6G). Analysis iron homeostasis TTP- <br />                                            deficient livers revealed significant change non-heme iron content (Figure S6F), <br />                                            TfR1or ferritin light chain protein (Figure S6G),  similar heart, Fpn1 protein <br />                                            expression suppressed. determine suppression Fpn1 protein                                            increased expression subsequent degradation hepcidin, measured levels                                            <span id='am-1' about='obo:IMR_0001700' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-2' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-3' property="obo:IAO_0000115" content="The polypeptide that is not a gene product." datatype="xsd:string"></span><span id='am-4' property="oboInOwl:id" content="IMR:0001700" datatype="xsd:string"></span><span id='am-5' property="rdfs:label" content="peptide" datatype="xsd:string"></span>peptide</span> TTP-deficient mouse livers.  consistent unaltered hepatic iron <br />                                            levels, protein content hepcidin similar TTP/TNFR1/2 KO WT mice <br />                                            (Figure S6H), suggesting different mechanism Fpn1 downregulation heart                                            liver. Taken  data mTOR TTP regulate TfR1 iron <br />                                            homeostasis vitro vivo, providing iron-regulatory pathway likely <br />                                            complements cellular functions IRP1/2. <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                            Page 8 <br />  <br />  <br />                               DISCUSSION <br />                                            Iron essential catalysis reactions appears intimate link <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            iron energy metabolism. Short-term iron deficiency known promote <br />                                            insulin sensitivity, iron overload lead glucose intolerance (Dongiovanni et al., <br />                                            2008; Liu et al., 2009). Iron accumulation linked non-alcoholic fatty liver disease, <br />                                            cause alteration function adipocytes ability oxidize glucose <br />                                            (Dongiovanni et al., 2011). cellular level, circumstantial evidence points                                            cross-talk energy sensing iron regulatory pathways, exemplified study <br />                                            Galvez et. al. identifies mTOR positive regulator transferrin-bound iron <br />                                            uptake (Galvez et al., 2007), iron deficiency shown inhibit mTOR signaling <br />                                            (Ndong et al., 2009; Ohyashiki et al., 2009).  direct systematic studies                                            mTOR iron regulation lacking.  pathway links mTOR,                                            major metabolic hub cell, regulation cellular iron uptake flux                                            modulation TfR1 expression. mechanism observed changes partially <br />                                            mediated TZF protein TTP, induced rapamycin, interacts TfR1 <br />                                            mRNA leads degradation (Figure 6H).  provide evidence <br />                                            TTP functions mammals similar yeast Cth1p/Cth2p regulating <br />                                            cellular iron reduction levels iron-containing proteins preservation                                            cell viability iron deficiency. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            possible vitro changes cellular iron content mTOR modulation                                            solely explained differential rates cellular division &#226;&#8364;&#339;iron-dilution&#226;&#8364;? effect,                                            increased iron levels rapamycin-treated terminally-differentiated mouse hearts argue <br />                                            possibility.  repressive effects rapamycin genes involved                                            cellular iron regulation specific pathway global transcriptional <br />                                            inhibition, levels iron-independent genes unaltered                                            increased rapamycin treatment. magnitude change iron levels mTOR <br />                                            modulation modest, suggesting mTOR fine-tune cellular iron utilization match <br />                                            metabolic requirements cell. Alternatively, modest change iron mTOR <br />                                            inhibition agreement hypothesis TTP involved iron conservation <br />                                            response. IRP1/2 activation enhances cellular iron uptake reduces export leading <br />                                            iron accumulation, TTP primarily affects distribution iron molecules                                            present cell large induction iron import storage. exact role TTP <br />                                            regulation iron homeostasis various environmental conditions remains                                            determined;  data highlight importance pathway low-iron states, <br />                                            evidenced severe loss cell viability iron deficiency TTP knockout. <br />  <br />                                            fact TTP reduces TfR1 mRNA levels stability surprising. TTP <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            strongly induced low iron levels different cell lines mouse hearts,                                            mechanistically distinct chelators.  appears counterintuitive TTP signals                                            degrade TfR1 message IRP1/2 concurrently stabilize mRNA. similar situation <br />                                            described yeast cells Aft1p  yeast homolog IRP1/2) activates                                            transcription FIT1 FIT2 genes involved iron uptake, Cth2p promotes                                            degradation response iron deficiency (Puig et al., 2005). hypothesize parallel <br />                                            activation pathways serves fine-tune TfR1 levels based severity iron <br />                                            deficiency degree reduction cellular iron utilization TTP. levels                                            iron-containing proteins decrease iron available, need additional <br />                                            import iron  corresponding reduction TfR1 levels. words, <br />                                            TTP act &#226;&#8364;&#339;brake&#226;&#8364;? IRP1/2 response better match rate iron import <br />                                            actual needs cell spare exogenous iron use tissues.                                            relative contribution TTP IRP1/2 pathways iron deficiency response remains                                            determined;  significant sequence overlap AREs IREs, binding <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                          Page 9 <br />  <br />  <br />                                            sites TTP IRP1/2, respectively, suggests possibility steric hindrance effects. <br />                                             rapid activation IRP1/2 slower transcriptional induction TTP                                            iron deficiency provide additional degree regulation, IRP1/2 serving <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            rapid response aimed correcting iron deficiency enhancing iron uptake.                                            unsuccessful, TTP-mediated iron-conservation program subsequently induced, <br />                                            allowing cells survive chronic iron deficiency. <br />  <br />                                            addition TTP, data suggest existence  unidentified, pathway <br />                                            mediating mTOR-dependent changes iron homeostasis.  observed                                            significant attenuation, complete reversal rapamycin effects TTP KO MEFs. <br />                                            Second, rapamycin administration caused rapid progressive reduction TfR1 <br />                                            mRNA levels, reaching significance hours treatment (n=18). induction <br />                                            TTP rapamycin represents later-stage response, acute mechanism,                                            phosphorylation event microRNA processing, explain findings.                                             presently unclear TTP expression regulated mTOR. induction                                            TTP rapamycin unaltered MEFs defective HIF IRP1/2 signaling, suggesting <br />                                            pathways involved mTOR-dependent regulation TTP.                                            unlikely rapamycin regulates TTP levels indirectly increase cellular iron <br />                                            levels, rapamycin iron chelation DFO additive,                                            opposing, effect TTP induction.  pathways downstream mTOR play                                            role regulation TTP cellular iron homeostasis.  data NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            exclude possibility independent roles mTOR TTP pathways regulation                                            TfR1 iron homeostasis. Extensive characterization molecular networks, <br />                                            environmental signals downstream effectors pathways shed light                                            biological role iron regulation. <br />  <br />                                            summary, identified mTOR TTP new players cellular iron homeostasis                                            regulate mRNA stability TfR1 iron-containing genes.  described                                            existence Cth1p/Cth2p-like pathway mammalian cells represent                                            important iron-deficiency response mechanism functions parallel  <br />                                            established IRP1/2 regulatory  <br />  <br />                               EXPREIMENTAL PROCEDURES <br />                               Cell culture reagents <br />                                            MEFs grown complete DMEM medium (Cellgro, VA) supplemented 10% FBS <br />                                            (Invitrogen, CA) 1% penicillin-streptomycin (P/S). glutamine-deprivation <br />                                            experiments Cellgro DMEM <span id='am-24' about='obo:IMR_0200448' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0001695 obo:IMR_0000001'><span id='am-25' property="rdfs:label" content="L-Glutamine" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-27' property="oboInOwl:id" content="IMR:0200448" datatype="xsd:string"></span><span id='am-28' property="oboInOwl:hasDbXref" content="KEGG:C00064" datatype="xsd:string"></span>L-glutamine</span> (Cat. # 15-013-CV) used.                                            genetically modified MEF lines compared matched WT MEFs obtained NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            littermate control mouse. TSC2 KO-V TSC2 KO-TSC2 MEFs described <br />                                            previously (Zhang et al., 2003). TTP KO (line 66) TTP WT (line 67) MEFs                                            derived littermate E14.5 embryos described (Taylor et al., 1996). ARNT KO MEFs <br />                                            generous gift Dr. Celeste Simon (Maltepe et al., 1997). IRP1 KO IRP2 KO <br />                                            MEFs kindly provided Dr. Tracey  Rouault. H9c2 cardiac myoblasts                                            purchased ATCC kept complete DMEM medium (ATCC, VA) 10% FBS <br />                                            1% P/S. H9c2 MEF cells treated 20nM rapamycin (LC Labs, MA) 24 <br />                                            48 hours, 150&#194;&#181;M DFO 200&#194;&#181;M 2,2-BPD 16&#226;&#8364;&#8220;24 hours unless specifically noted,                                            50&#194;&#181;g/ml FAC 16 hrs (Sigma-Aldrich, USA). <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                         Page 10 <br />  <br />  <br />                               siRNA treatment <br />                                              H9c2 cells transfected siRNA using DharmaFect (Thermo Scientific,  reagent <br />                                              according manufacturer&#226;&#8364;&#8482;s protocol. Rat TSC2 siGENOME siRNA (Thermo Scientific, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               rat TTP FlexiTube siRNA (Quiagen, CA) used. <br />  <br />                               Quantitiative RT-PCR <br />                                              RNA isolated RNA STAT-60 (TEL-TEST,  TX), reverse-transcribed                                              Random Hexamer (Applied Biosystems, CA), amplified 7500 Fast Real-Time PCR <br />                                              SYBR Green PCR Master Mix (Applied Biosystems, CA). Primers                                              designed using Primer3 (v. 0.4.0) software target sequences spanning exon-intron-exon <br />                                              boundary. mRNA levels calculated comparative threshold cycle method                                              normalized &#206;&#178;-actin HPRT gene. <br />  <br />                               Western blot <br />                                              30 &#194;&#181;g protein resolved SDS-PAGE gels transferred nitrocellulose <br />                                              membranes (Invitrogen, CA) probed antibodies pS6 (Cell <br />                                              Signaling, MA), TfR1 (Invitrogen, CA), Slc40A1 (Fpn1, Novus Biologicals, , TTP (Cao <br />                                              et al., 2004) Tubulin (Abcam, MA). HRP-conjugated donkey anti-rabbit donkey <br />                                              anti-mouse used secondary antibodies (Santa Cruz, CA) visualized Pierce <br />                                              SuperSignal Chemiluminescent Substrates. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Plasmid transfections <br />                                              Plasmids transfected MEFs using Lipofectamine reagent (Invitrogen, CA)                                              OptiMEM (Cellgro, VA) hours, followed incubation complete, antibiotic-free <br />                                              medium 20 hours. <br />  <br />                               Non-heme heme iron assays <br />                                              Non-heme iron measured described (Rebouche et al., 2004). Briefly, equal amounts <br />                                              protein mixed protein precipitation solution (1:1 1N HCl 10% <br />                                              trichloroacetic acid) heated 95&#194;&#176;C 1h release iron. Precipitated protein                                              removed centrifugation 4&#194;&#176;C 16,000 &#195;&#8212; g 10 minutes, supernatant                                              mixed equal volume chromogen solution (0.5mM ferrozine, 1.5M sodium <br />                                              acetate, 0.1% (v/v) thioglycolic acid) absorbance measured Spectra Max Plus <br />                                              microplate reader 562 nm. Heme quantified described (Ward et al., 1984). Briefly, <br />                                              equal amounts protein mixed 2M oxalic acid, heated 95&#194;&#176;C 30 minutes                                              release iron heme generate <span id='am-19' about='obo:IMR_0200089' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-20' property="rdfs:label" content="Protoporphyrin IX" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:id" content="IMR:0200089" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:hasDbXref" content="KEGG:C02191" datatype="xsd:string"></span><span id='am-23' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>protoporphyrin IX</span>. Samples centrifuged                                              10 min 1,000 &#195;&#8212; g 4&#194;&#176;C remove debris, fluorescence supernatant NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              assessed 405nm / 600nm Spectra Max Gemini fluorescence microplate reader. <br />  <br />                               55Fe    uptake studies <br />                                              55Fe  (Perkin-Elmer, MA) conjugated nitriloacetic acid (NTA, Sigma-Aldrich, USA) <br />                                              dissolved final concentration 100&#226;&#8364;&#8220;300nM complete, serum-containing <br />                                              medium 24 hours prior beginning experiments. MEFs H9c2 incubated <br />                                              1 hour 24 hours 55Fe-containing complete medium, washed 3 times ice- <br />                                              cold 500mM BPS PBS remove membrane-associated 55Fe lysed 1% <br />                                              Triton-X100 TBS. radioactivity sample determined Beckman <br />                                              scintillation counter normalized protein content sample. <br />  <br />  <br />  <br />  <br />                                                 Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                         Page 11 <br />  <br />  <br />                               mRNA stability assay <br />                                            MEFs incubated complete medium supplemented 5&#194;&#181;M actinomycin D <br />                                            (Sigma-Aldrich, USA) 3&#226;&#8364;&#8220;6 hours. drop cell viability observed end NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            treatment. RNA collected mRNA levels analyzed qRT-PCR                                            described  <br />  <br />                               RNA-CoIP <br />                                            protocol adapted Emmons et. al (Emmons et al., 2008) following <br />                                            modifications. HEK-293 cells resuspended Buffer (10mM Tris&#226;&#8364;&#8220;HCl pH 7.6, 1mM <br />                                            KAc, 1.5mM MgAc, 2mM DTT, 10&#194;&#181;l/ml Protease Arrest inhibitors), lysed using Power <br />                                            Gen 500 homogenizer (Fisher Scientific, PA), followed centrifugation 12,000 &#195;&#8212; g                                            10 min 4&#194;&#176;C remove debris. Protein G Sepharose Fast Flow beads (Sigma-Aldrich, <br />                                            USA) incubated human TTP (kindly provided Dr. William Rigby, Dartmouth <br />                                            University) IgG antibody IP Buffer (10mM Tris-HCl pH 7.6, 1.5mM MgCl2, <br />                                            100mM NaCl, 0.5% Triton X-100, 10&#194;&#181;l/ml Protease Arrest inhibitors) 4&#194;&#176;C                                            continuous rotation 4 hours. Beads washed 6 times cold IP buffer                                            incubated HEK-293 lysate 4&#194;&#176;C continuous rotation 2 hours. RNA                                            collected equal amounts amplified qRT-PCR. Expression gene                                            normalized 18S data expressed fold enrichment IgG control. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Luciferase Assay <br />                                            Luciferase assay TfR1-3&#226;&#8364;&#8482;UTR-Luc various deletion constructs performed <br />                                            using Dual Glo Luciferase Assay (Promega) according manufacturer&#226;&#8364;&#8482;s <br />                                            protocol. 3&#226;&#8364;&#8482; UTR TfR1 cloned pMIR-report vector containing gene                                            firefly luciferase (Ambion) confirmed sequencing. luminescence quantified <br />                                            Berthold Technologies Luminometer (Germany) Dual-Glo&#194;&#174; Stop <span id='am-12' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-13' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-14' property="rdfs:label" content="AMP" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-17' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-18' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span>amp</span>; Glo&#194;&#174; <br />                                            reagent added quench firefly luminescence provide substrate renilla <br />                                            luminescence used normalize transfection efficiency. <br />  <br />                               Cell death studies <br />                                            Cell death assessed labeling PI (Sigma-Aldrich, USA) Alexa Fluor&#194;&#174; <br />                                            350-conjugated Annexin V (Molecular Probes, NY), analyzed flow cytometry                                            FacsCanto flow cytometer (BD Bioscience). cell-cycle studies, cells incubated <br />                                            rapamycin 6 hours incubated DFO rapamycin 10-hours prior                                            collection. Cells collected trypsinization, washed, fixed 70% ethanol                                            &#226;&#710;&#8217;20&#194;&#176;C hours, followed incubation PI staining solution (50&#194;&#181;g/mL PI, <br />                                            0.2mg/ml RNAse  0.1% Triton X-100 PBS) 37&#194;&#176;C 20 minutes. Cell cycle NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            analyzed flow cytometry FlowJo 7.6 software. <br />  <br />                               Mouse studies <br />                                            Wild-type C57BL/6 females purchased Jackson labs treated 5 daily <br />                                            intraperitoneal injections rapamycin 10mg/kg DMSO. Mice anesthetized <br />                                            250mg/kg dose freshly-prepared Tribromoethanol (Avertin) harvested <br />                                            organs flash-frozen liquid nitrogen. animal studies conducted                                            accordance Northwestern University animal care guidelines. <br />  <br />                               Yeast studies <br />                                            Yeast cth1&#206;&#8221;cth2&#206;&#8221; cells transformed pRS416 vector expressing CTH2, TTP                                            TTP-C124R control CTH2 promoter region grown synthetic media <br />                                            containing 300&#194;&#181;M iron (+ Fe) 100&#194;&#181;M Fe2+-specific chelator bathophenanthroline <br />                                            disulfonic acid (&#226;&#710;&#8217; Fe), RNA extracted analyzed RNA blotting previously <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                                            Page 12 <br />  <br />  <br />                                            described (Puig et al., 2005). Actin (ACT1) mRNA levels used loading control. <br />                                            Wild-type yeast cells exponential phase growth treated 1&#194;&#181;g/mL                                            rapamycin 16 hours, following mRNA collected expression Cth1/2 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            genes analyzed qRT-PCR. <br />  <br />                               Statistical analysis <br />                                            Data expressed mean &#194;&#177; SEM. Statistical significance assessed unpaired <br />                                            Student t test; P value 0.05 considered statistically significant. <br />  <br />                               Supplementary Material <br />                                            Refer Web version PubMed Central supplementary material. <br />  <br />  <br />                               Acknowledgments <br />                                            thank Dr. Seth  Brooks help TTP RNA-CoIP experiments, Drs. Sarah Rice, Navdeep Chandel                                            Elizabeth Leibold critical review manuscript, Drs. William F.C. Rigby, M. Celeste Simon                                            Tracey  Rouault generous gifts human TTP antibody, ARNT KO MEFs, IRP1 2 KO <br />                                            MEFs respectively. work supported Northwestern University Flow Cytometry Facility                                            Cancer Center Support Grant (NCI CA060553). M.B. H  designed research. M.B., K. S.P. <br />                                            performed experiments data analysis. P.J.B S.P. provided tools reagents. M.B. wrote                                            manuscript, authors commented  H  supervised project. M.B. supported American <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Heart Association 10PRE4430021. H  supported NIH grants K02 HL107448 R01 HL087149. <br />  <br />  <br />                               REFERENCES <br />                                            Aisen P, Enns C, Wessling-Resnick M. Chemistry biology eukaryotic iron metabolism. Int J <br />                                              Biochem Cell Biol. 2001; 33:940&#226;&#8364;&#8220;959. [PubMed: 11470229] <br />                                            Altamura S, Muckenthaler MU. Iron toxicity diseases aging: Alzheimer&apos;s disease, Parkinson&apos;s <br />                                              disease atherosclerosis. J Alzheimers Dis. 2009; 16:879&#226;&#8364;&#8220;895. [PubMed: 19387120] <br />                                            Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci. 2009; 66:3241&#226;&#8364;&#8220;3261. <br />                                              [PubMed: 19484405] <br />                                            Arredondo M, Nunez MT. Iron copper metabolism. Mol Aspects Med. 2005; 26:313&#226;&#8364;&#8220;327. <br />                                              [PubMed: 16112186] <br />                                            Baou M, Jewell  Murphy JJ. TIS11 family proteins roles posttranscriptional gene <br />                                              regulation. J Biomed Biotechnol. 2009; 2009:634520. [PubMed: 19672455] <br />                                            Briata P, Ilengo C, Corte G, Moroni C, Rosenfeld MG, Chen CY, Gherzi R. Wnt/beta-catenin-- <br />                                              &gt;Pitx2 pathway controls turnover Pitx2 unstable mRNAs. Mol Cell. 2003; <br />                                              12:1201&#226;&#8364;&#8220;1211. [PubMed: 14636578] <br />                                            Cao H, Tuttle JS, Blackshear PJ. Immunological characterization tristetraprolin low abundance, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              inducible, stable cytosolic protein. J Biol Chem. 2004; 279:21489&#226;&#8364;&#8220;21499. [PubMed: 15010466] <br />                                            Carballo E, Blackshear PJ. Roles tumor necrosis factor-alpha receptor subtypes pathogenesis <br />                                              tristetraprolin-deficiency syndrome. Blood. 2001; 98:2389&#226;&#8364;&#8220;2395. [PubMed: 11588035] <br />                                            Carrick DM, Lai WS, Blackshear PJ. tandem CCCH zinc finger protein tristetraprolin                                              relevance cytokine mRNA turnover arthritis. Arthritis Res Ther. 2004; 6:248&#226;&#8364;&#8220;264. [PubMed: <br />                                              15535838] <br />                                            Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron fatty liver metabolic <br />                                                syndrome: promising therapeutic target. J Hepatol. 2011; 55:920&#226;&#8364;&#8220;932. [PubMed: 21718726] <br />                                            Dongiovanni P, Valenti L, Ludovica Fracanzani  Gatti S, Cairo G, Fargion S. Iron depletion                                                deferoxamine regulates glucose uptake insulin signaling hepatoma cells rat liver. <br />                                                J Pathol. 2008; 172:738&#226;&#8364;&#8220;747. [PubMed: 18245813] <br />                                            Dunlop EA, Tee AR. Mammalian target rapamycin complex 1: signalling inputs, substrates                                                feedback mechanisms. Cell Signal. 2009; 21:827&#226;&#8364;&#8220;835. [PubMed: 19166929] <br />  <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                                   Page 13 <br />  <br />  <br />                                            Emmons J, Townley-Tilson WH, Deleault KM, Skinner SJ, Gross RH, Whitfield ML, Brooks SA. <br />                                                Identification TTP mRNA targets human dendritic cells reveals TTP critical regulator                                                dendritic cell maturation. RNA. 2008; 14:888&#226;&#8364;&#8220;902. [PubMed: 18367721] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pages G. Tristetraprolin inhibits Ras-dependent <br />                                                tumor vascularization inducing vascular endothelial growth factor mRNA degradation. Mol <br />                                                Biol Cell. 2007; 18:4648&#226;&#8364;&#8220;4658. [PubMed: 17855506] <br />                                            Galvez T, Teruel MN, Heo WD, Jones JT, Kim ML, Liou J, Myers JW, Meyer T. siRNA screen                                                human signaling proteome identifies PtdIns(3,4,5)P3-mTOR signaling pathway primary <br />                                                regulator transferrin uptake. Genome Biol. 2007; 8:R142. [PubMed: 17640392] <br />                                            Hentze MW, Muckenthaler MU, Galy B, Camaschella C. tango: regulation Mammalian iron <br />                                                metabolism. Cell. 2010; 142:24&#226;&#8364;&#8220;38. [PubMed: 20603012] <br />                                            Howell JJ, Manning BD. mTOR couples cellular nutrient sensing organismal metabolic <br />                                                homeostasis. Trends Endocrinol Metab. 2011; 22:94&#226;&#8364;&#8220;102. [PubMed: 21269838] <br />                                            Kakuta K, Orino K, Yamamoto S, Watanabe K. High levels ferritin iron fetal bovine <br />                                                serum. Comp Biochem Physiol Physiol. 1997; 118:165&#226;&#8364;&#8220;169. [PubMed: 9243818] <br />                                            Kim MJ, Mayr M, Pechula M, Steiger J, Dickenmann M. Marked erythrocyte microcytosis                                                primary immunosuppression sirolimus. Transpl Int. 2006; 19:12&#226;&#8364;&#8220;18. [PubMed: 16359372] <br />                                            Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. Evidence                                                tristetraprolin binds AU-rich elements promotes deadenylation destabilization                                                tumor necrosis factor alpha mRNA. Mol Cell Biol. 1999; 19:4311&#226;&#8364;&#8220;4323. [PubMed: 10330172] <br />                                            Liu Q, Sun L, Tan Y, Wang G, Lin X, Cai L. Role iron deficiency overload pathogenesis <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                diabetes diabetic complications. Curr Med Chem. 2009; 16:113&#226;&#8364;&#8220;129. [PubMed: 19149565] <br />                                            Maiorano  Stallone G, Schena  Infante B, Pontrelli P, Schena FP, Grandaliano G. Sirolimus <br />                                                interferes iron homeostasis renal transplant recipients. Transplantation. 2006; 82:908&#226;&#8364;&#8220;912. <br />                                                [PubMed: 17038905] <br />                                            Maltepe E, Schmidt JV, Baunoch D, Bradfield CA, Simon MC. Abnormal angiogenesis responses <br />                                                glucose oxygen deprivation mice lacking protein ARNT. Nature. 1997; 386:403&#226;&#8364;&#8220;407. <br />                                                [PubMed: 9121557] <br />                                            Ndong M, Kazami M, Suzuki T, Uehara M, Katsumata S, Inoue H, Kobayashi K, Tadokoro T, Suzuki <br />                                                K, Yamamoto Y. Iron deficiency regulates Akt/TSC1-TSC2/mammalian Target                                                Rapamycin signaling pathway rats COS-1 cells. Nutr Res. 2009; 29:640&#226;&#8364;&#8220;647. [PubMed: <br />                                                19854379] <br />                                            Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K. oral iron chelator <br />                                                deferasirox represses signaling mTOR myeloid leukemia cells enhancing <br />                                                expression REDD1. Cancer Sci. 2009; 100:970&#226;&#8364;&#8220;977. [PubMed: 19298223] <br />                                            Patel SA, Simon MC. Biology hypoxia-inducible factor-2alpha development disease. Cell <br />                                                Death Differ. 2008; 15:628&#226;&#8364;&#8220;634. [PubMed: 18259197] <br />                                            Pedro-Segura E, Vergara SV, Rodriguez-Navarro S, Parker R, Thiele DJ, Puig S. Cth2  <br />                                                binding protein recruits Dhh1 helicase promote decay succinate dehydrogenase SDH4 <br />                                                mRNA response iron deficiency. J Biol Chem. 2008; 283:28527&#226;&#8364;&#8220;28535. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                18715869] <br />                                            Puig S, Askeland E, Thiele DJ. Coordinated remodeling cellular metabolism iron deficiency <br />                                                targeted mRNA degradation. Cell. 2005; 120:99&#226;&#8364;&#8220;110. [PubMed: 15652485] <br />                                            Puig S, Vergara SV, Thiele DJ. Cooperation mRNA-binding proteins drives metabolic <br />                                                adaptation iron deficiency. Cell Metab. 2008; 7:555&#226;&#8364;&#8220;564. [PubMed: 18522836] <br />                                            Rebouche CJ, Wilcox CL, Widness JA. Microanalysis non-heme iron animal tissues. J Biochem <br />                                                Biophys Methods. 2004; 58:239&#226;&#8364;&#8220;251. [PubMed: 15026210] <br />                                            Rouault TA. role iron regulatory proteins mammalian iron homeostasis disease. Nat <br />                                                Chem Biol. 2006; 2:406&#226;&#8364;&#8220;414. [PubMed: 16850017] <br />                                            Sengupta S, Peterson TR, Sabatini DM. Regulation mTOR complex 1 pathway nutrients, <br />                                                growth factors, stress. Mol Cell. 2010; 40:310&#226;&#8364;&#8220;322. [PubMed: 20965424] <br />                                            Sofroniadou S, Kassimatis T, Goldsmith D. Anaemia, microcytosis sirolimus- iron missing <br />                                                link? Nephrol Dial Transplant. 2010; 25:1667&#226;&#8364;&#8220;1675. [PubMed: 20054028] <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                                Page 14 <br />  <br />  <br />                                            Soliman GA. mammalian target rapamycin signaling network gene regulation. Curr Opin <br />                                                Lipidol. 2005; 16:317&#226;&#8364;&#8220;323. [PubMed: 15891393] <br />                                            Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Broxmeyer  Haynes BF, et al. pathogenetic role TNF alpha syndrome cachexia, <br />                                                arthritis, autoimmunity resulting tristetraprolin (TTP) deficiency. Immunity. 1996; <br />                                                4:445&#226;&#8364;&#8220;454. [PubMed: 8630730] <br />                                            Torti SV, Torti FM. Ironing cancer. Cancer Res. 2011; 71:1511&#226;&#8364;&#8220;1514. [PubMed: 21363917] <br />                                            Wang J, Pantopoulos K. Regulation cellular iron metabolism. Biochem J. 2011; 434:365&#226;&#8364;&#8220;381. <br />                                                [PubMed: 21348856] <br />                                            Ward JH, Jordan  Kushner JP, Kaplan J. Heme regulation HeLa cell transferrin receptor number. J <br />                                                Biol Chem. 1984; 259:13235&#226;&#8364;&#8220;13240. [PubMed: 6092369] <br />                                            Weinberg ED. hazards iron loading. Metallomics. 2010; 2:732&#226;&#8364;&#8220;740. [PubMed: 21072364] <br />                                             Worldwide prevalence anaemia 1993&#226;&#8364;&#8220;2005. Geneva, Switzerland: Press; 2008. <br />                                            Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, <br />                                                Kwiatkowski DJ. Loss Tsc1/Tsc2 activates mTOR disrupts PI3K-Akt signaling                                                downregulation PDGFR. J Clin Invest. 2003; 112:1223&#226;&#8364;&#8220;1233. [PubMed: 14561707] <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                      Page 15 <br />  <br />  <br />                                                                                  HIGHLIGHTS <br />                                            &#226;&#8364;&#162;    mTOR regulates iron homeostasis altering expression iron transporters <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            &#226;&#8364;&#162;    TTP regulates iron homeostasis, similar yeast Cth1p/2p <br />                                            &#226;&#8364;&#162;    mTOR regulates TfR1 iron homeostasis TTP <br />                                            &#226;&#8364;&#162;    TfR1 mRNA target TTP <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                        Page 16 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 1. mTOR regulates cellular iron content uptake <br />                                              mTOR modulation MEFs (left) H9c2 (right) cells assessed Western blot                                            phosphorylated S6 protein. Densitometry analysis shown Western blot (n=3). <br />                                            TSC2 protein levels (right) TSC2 KO-V TSC2 KO-TSC2 MEFs. (B) Non-heme iron <br />                                            content WT MEFs treated 20nM rapamycin 48 hrs normalized protein <br />                                            concentration (n=12). subsequent experiments carried 20nM rapamycin <br />                                            treatment 48 hrs mammalian cell lines, unless noted  (C) Non-heme iron <br />                                            content TSC2 KO-V TSC2 KO-TSC2 MEFs rapamycin treatment <br />                                            (n=6&#226;&#8364;&#8220;12). (D) Radioactive iron uptake 1 hour WT MEFs rapamycin vehicle <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                    Page 17 <br />  <br />  <br />                                            control treatment (n=12). (E) Radioactive iron uptake 1 hour TSC2 KO-V TSC2 <br />                                            KO-TSC2 MEFs rapamycin (n=6&#226;&#8364;&#8220;12). (F) Cellular content 55Fe WT <br />                                            MEFs treated rapamycin vehicle control following 24-hour incubation NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            radioactive iron (n=12). (G) Cellular content 55Fe TSC2 KO-V TSC2 KO-TSC2 <br />                                            MEFs rapamycin following 24-hour incubation radioactive iron <br />                                            (n=6). Data presented mean &#194;&#177; SEM. * p&lt;0.05 vs. control, # p&lt;0.05 vs. TSC2 KO-V <br />                                            MEFs. Figure S1. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                      Page 18 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 2. mTOR regulates expression iron transporters <br />                                            Protein levels TfR1 WT MEFs   Fpn1 mouse hearts (B) following rapamycin <br />                                            treatment. Densitometry analyses presented Western blots. (C) mRNA levels <br />                                            iron transporters, TfR1 Fpn1, determined qRT-PCR, WT MEFs                                            rapamycin treatment (n=6&#226;&#8364;&#8220;12). (D) mRNA levels iron transporters TSC2 KO- <br />                                            V TSC2 KO-TSC2 MEFs rapamycin treatment (n=6&#226;&#8364;&#8220;12). (E) mRNA <br />                                            levels genes unrelated iron homeostasis WT MEFs treated rapamycin vehicle <br />                                            control (n=6). Data presented mean &#194;&#177; SEM. * p&lt;0.05 vs. control, # p&lt;0.05 vs. TSC2 <br />                                            KO-V MEFs. Figure S2. <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                       Page 19 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 3. TTP functionally similar yeast Cth1p/2p <br />                                              Time-course TfR1 Fpn1 mRNA regulation rapamycin WT MEFs 24 <br />                                            hrs (n=12&#226;&#8364;&#8220;18). (B) TfR1 mRNA stability WT MEFs rapamycin pre- <br />                                            treatment assessed qRT-PCR incubation transcriptional inhibitor <br />                                            actinomycin D (act D), normalized TfR1 mRNA levels time point zero respective <br />                                            group (n=3). (C) IRP1 mRNA levels IRP2 KO MEFs following treatment IRP1 <br />                                            siRNA (n=6). (D) TfR1 mRNA levels IRP1/2 KD/KO MEFs following rapamycin <br />                                            treatment (n=6). TTP mRNA (E) TTP protein (F) levels WT MEFs DFO <br />                                            treatment 16 hours (n=3&#226;&#8364;&#8220;6). Densitometry analysis presented Western blot. <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                       Page 20 <br />  <br />  <br />                                            (G) TTP mRNA levels H9c2 cells 16-hour incubation 2,2-BPD FAC iron <br />                                            chelation overload, respectively (n=6). (H) mRNA levels iron-containing proteins                                            WT MEFs treated 150&#194;&#181;M DFO 16 hours (n=6). Unless noted  NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            subsequent studies performed using protocol iron chelation DFO.   <br />                                            mRNA levels iron-containing proteins TTP WT KO MEFs (n=12&#226;&#8364;&#8220;18). (J) mRNA <br />                                            levels iron-containing proteins TTP KO WT MEFs presence absence                                            DFO (n=6&#226;&#8364;&#8220;12). (K) mRNA levels iron-containing Cth2p targets cth1&#206;&#8221;cth2&#206;&#8221; yeast <br />                                            ectopic expression human wild-type TZF mutant TTP. Data presented                                            mean &#194;&#177; SEM. * p&lt;0.05 vs. control, # p&lt;0.05 vs. control 180 minutes. Figure S3. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                  Page 21 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 4. mTOR regulates TTP expression <br />                                            TTP mRNA   TTP protein (B) levels WT MEFs treated rapamycin (n=6&#226;&#8364;&#8220;8). <br />                                            (C) TTP mRNA levels TSC2 KO-V TSC2 KO-TSC2 MEFs                                            rapamycin treatment (n=6&#226;&#8364;&#8220;12). (D) Cth1 Cth2 mRNA levels WT yeast cells treated <br />                                            1&#194;&#181;g/mL rapamycin 24 hours (n=6). mRNA levels TTP ARNT KO MEFs <br />                                            treated rapamycin (E) DFO (F) (n=15). TTP mRNA levels IRP1/2 KD/KO MEFs <br />                                            treated rapamycin (G) DFO (H) (n=6).   TfR1 mRNA levels TTP KO                                            control MEFs (n=15). (J) TfR1 mRNA levels WT MEFs transfected TTP- GFP- <br />                                            containing (control) vectors (n=6). (K) TfR1 mRNA stability TTP WT KO MEFs <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                         Page 22 <br />  <br />  <br />                                            treated transcriptional inhibitor act D (n=6). Data presented mean &#194;&#177; SEM. * <br />                                            p&lt;0.05 vs. control. Figure S4. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                       Page 23 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 5. mTOR regulates TfR1 TTP <br />                                              Schematic representation TfR1-3&#226;&#8364;&#8482;UTR-Luc construct IREs indicated white <br />                                            putative AREs grey. Luciferase assay TfR1-3&#226;&#8364;&#8482;UTR activity WT MEFs <br />                                            overexpressing TTP (B) TTP KO WT MEFs (C), normalized renilla luciferase <br />                                            (n=6). (D) mRNA levels TfR1 total RNA precipitated TTP IgG (control) <br />                                            antibodies HEK293 cells. primer sets targeting different regions near 3&#226;&#8364;&#8482;UTR                                            TfR1 gene used RNA IP assay normalized 18S internal control. <br />                                            Data presented fold enrichment IgG control (n=3). (E) mRNA levels TfR1 <br />                                            TTP WT KO MEFs treated rapamycin vehicle control (n=12). (F) mRNA <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                      Page 24 <br />  <br />  <br />                                            levels ABCE1 Lias TTP WT KO MEFs rapamycin treatment <br />                                            (n=12). (G) TfR1 mRNA stability 3-hour incubation act D WT TTP KO <br />                                            MEFs presence absence rapamycin. Data presented fold change TfR1 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            mRNA levels time point zero respective group (n=3&#226;&#8364;&#8220;6). (H) TfR1 mRNA levels <br />                                            TTP WT KO MEFs DFO treatment (n=6).   Cell death assessed <br />                                            propidium iodine (PI) Annexin V labeling flow cytometry TTP WT KO <br />                                            MEFs treated 250&#194;&#181;M DFO 250&#194;&#181;M 2,2-BPD 40 hours normalized                                            vehicle-treated control (n=4). (J) Cell death TTP KO MEFs 16-hour pre- <br />                                            treatment rapamycin incubated 250&#194;&#181;M DFO 250&#194;&#181;M 2,2-BPD 40 hours                                            rapamycin (n=4). Data presented mean &#194;&#177; SEM. * p&lt;0.05 vs. control, # <br />                                            p&lt;0.05 vs. rapamycin pre-treated control group. Rapa, rapamycin. Figure S5. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                       Page 25 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Figure 6. vivo regulation iron homeostasis mTOR TTP <br />                                            Non-heme   heme (B) iron levels hearts c57 black WT mice treated 5 <br />                                            daily IP injections rapamycin, 10mg/kg (n=6), equal volume DMSO vehicle. (C) <br />                                            TfR1 Fpn1 mRNA levels hearts rapamycin-treated mice (n=6). (D) Western <br />                                            blot analysis rapamycin-treated mouse hearts. Densitometry analysis presented                                            Western blots (n=3). (E). Western blot analysis TfR1 protein hearts TTP/ <br />                                            TNFR1/2 KO (designated TTP KO) matched littermate WT control mice (designated <br />                                            TTP WT). Densitometry analysis presented right Western blot (n=3). (F) <br />                                            Non-heme iron levels hearts TTP KO WT mice (n=4). (G) Western blot <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                         Page 26 <br />  <br />  <br />                                            analysis ferritin light heavy chains (FtL + FtH) Fpn1 proteins hearts                                            TTP KO WT mice. Densitometry analysis presented Western blots (n=4). <br />                                            (H) Model cellular iron regulation mTOR TTP. Data presented mean &#194;&#177; <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            SEM. * p&lt;0.05. Figure S6. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               Cell Metab. Author manuscript; available PMC 2013 November 07. <br />                             Bayeva et al.                                                                                      Page 27 <br />  <br />  <br />  <br />  <br />                                                                                         Table 1 <br />                                                 Interaction TTP TfR1 mRNA <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            RNA-CoIP experiment using specific TTP antibody control IgG antibody bait establishes physical <br />                            interaction TTP TfR1 mRNA. distinct sets primers designed target regions                            TfR1 mRNA adjacent 3&#226;&#8364;&#8482;UTR. Relative mRNA levels assessed qRT-PCR displayed                            fold enrichment IgG control. VEGF1 Pitx-2 used positive controls, &#206;&#178;2-microglobulin, <br />                            Fpn1, HPRT 18S rRNA used negative controls. Figure S6 <br />  <br />                             Gene                    Relative Expression   Relative Expression   Fold Enrichment <br />                                                     IgG                   TTP                   IgG Control <br />  <br />                             Transferrin Receptor <br />  <br />                               TfR1-1                281.81                426.31                1.51 <br />  <br />                               TfR1-2                528.61                672.54                1.27 <br />  <br />                               TfR1-3                268.16                381.56                1.42 <br />  <br />                               TfR1-4                266.13                369.66                1.45 <br />  <br />                             Positive Controls <br />  <br />                               VEGF-1                1931.18               3678.42               1.90 <br />  <br />                               VEGF-2                2048.95               3982.25               1.94 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                               Pitx2-1               2082.60               1960.18               0.94 <br />  <br />                               Pitx2-2               690.53                984.72                1.43 <br />  <br />                             Negative Controls <br />  <br />                               &#206;&#178;2MG                  22080.25              19099.78              0.87 <br />  <br />                     <br /> </body></html>